Longer-term follow-up of patients with refractory and relapsed diffuse large B-cell lymphoma (DLBCL) who received chimeric antigen receptor (CAR) T cell therapy showed sustained responses in about half of the patients, suggesting that CAR-T therapy may be an effective option for this hard-to-treat non-Hodgkin's lymphoma, according to the ZUMA-1* and JULIET** trials presented at ASH 2017.
Combining aspirin with warfarin led to increased bleeding complications in patients with atrial fibrillation (AF) or venous thromboembolic disease (VTE) compared with warfarin alone, resulting in higher rates of major bleeding events and hospital admissions, according to data presented at ASH 2017.
Defibrotide treatment may be beneficial to adult patients with posthematopoietic stem cell transplantation (HSCT) hepatic veno-occlusive disease/sinusoidal obstruction syndrome (VOD/SOS), reports a new study presented at the concluded 59th American Society of Haematology Annual Meeting (ASH 2017).
Use of idelalisib plus ofatumumab in the frontline treatment of chronic lymphocytic leukaemia (CLL) is effective, yielding high overall response rate, although this is counterbalanced by significant toxicities, according to efficacy data from a phase II trial.
In the first-line treatment of Philadelphia chromosome-positive chronic myeloid leukaemia (CML), patients presenting BCR-ABL1 transcript levels ≤10 percent at 3 months are more likely to achieve major molecular response at 12 months with faster response rate compared with those who have transcript levels >10 percent, according to ≥12 months of follow-up data from the BFORE* trial.
Treatment with defibrotide is safe and effective for patients with veno-occlusive disease (VOD), also known as sinusoidal obstruction syndrome (SOS), following either allogeneic or autologous haematopoietic stem cell transplant (HSCT), according to the results of a study presented at the 59th American Society of Hematology (ASH) Annual Meeting and Exhibition in Atlanta, Georgia.
Once-weekly subcutaneous administration of the bispecific humanized monoclonal antibody emicizumab successfully prevented or reduced bleeds with a favourable safety profile in paediatric patients with haemophilia A with inhibitors in the phase III HAVEN-2* trial, confirming the findings of a previous interim analysis.
Platelet count thresholds <20 x 109/L and <10 x 109/L are associated with major increased risk for both any and mucosal bleeding. Furthermore, platelet count, female sex and exposure to nonsteroidal anti-inflammatory drugs (NSAIDs) are risk factors for the risk of any bleeding, according to a study presented at the 59th American Society of Hematology (ASH) Annual Meeting and Exposition in Atlanta, Georgia.
In newly diagnosed, transplant-eligible multiple myeloma (MM) patients, induction therapy with cyclophosphamide-bortezomib-dexamethasone (CyBorD) delivers a comparable efficacy to bortezomib-dexamethasone (Vel-Dex), according to a new study presented at the recently concluded 59th American Society of Hematology Annual Meeting (ASH 2017).
The choice between nonvitamin K antagonist oral anticoagulants (NOACs) or vitamin K antagonists (VKAs) for stroke prevention appears to be complex and largely heterogenous across different, countries, a new study has found.
Monotherapy with tenofovir disoproxil fumarate increases virologic response for up to 240 weeks in pretreated patients with hepatitis B virus infection (HBV) who are resistant to entecavir and/or adefovir, a new study has found.
Long-term treatment with the interleukin-5
receptor alpha-directed cytolytic monoclonal antibody benralizumab led to long-term control of asthma, improvement in pulmonary function, and was safe in patients with severe eosinophilic asthma in the 2-year integrated analysis of the SIROCCO, CALIMA, and ZONDA pivotal studies plus the BORA extension study reported at ATS 2019.
Emerging evidence is showing that the two major new classes of antidiabetic drugs — SGLT2* inhibitors and GLP-1** receptor agonists (RAs) — not only confer cardiovascular (CV) benefits to patients with type 2 diabetes (T2D), they also delay the loss of kidney function among these patients, potentially providing nephrologists with an additional tool in their armamentarium for managing patients with chronic kidney disease (CKD) in the future.